Sacituzumab govitecan (brand name: TRODELVY®) is a new treatment for certain types of advanced or metastatic breast cancer. One common type of breast cancer has at least 1 of 2 hormone receptors (HR positive) and does not have human epidermal growth factor 2 (HER2 negative). The HR and HER2 receptors are known to influence how severe a case of breast cancer is. Certain treatments will only work if a specific receptor is present on breast cancer cells. HR-positive/HER2-negative advanced or metastatic breast cancer can be treated with sacituzumab govitecan. This is a summary of the results of the TROPiCS-02 study. This study compared sacituzumab govitecan with standard chemotherapy in participants with HR-positive/HER2-negative advanced or metastatic breast cancer. This Plain Language Summary of Publication article (PLSP) from Future Oncology summarises a study called TROPiCS-02 that compared the effectiveness of a medication called sacituzumab govitecan with standard chemotherapy in treating participants with a type of breast cancer called HR-positive/HER2-negative advanced or metastatic breast cancer.

Visit the Future Medicine using the link to read the article.

This PLSP is based on two original articles, the first original article on which this summary is based is called ‘Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer’ and was published in the Journal of Clinical Oncology.

Visit ASCO Publications using the link to read the article.

The second original article on which this summary is based is called ‘Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial’ and was published in the The Lancet.

Visit The Lancet using the link to read the article.